相关临床试验
693
114 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1966
进行中（未招募）
31
4.5%
已完成
309
44.6%
Enrolling By Invitation
10
1.4%
尚未招募
73
10.5%
招募中
123
17.8%
暂停
2
0.3%
终止
45
6.5%
Unknown
85
12.3%
撤回
15
2.2%
暂无批准数据
- University of Calgary researchers developed GCAR1, a first-in-class CAR T-cell therapy targeting a novel marker on solid tumors, published in Nature and Nature Cancer. - Two patients with alveolar soft-cell sarcoma received the therapy; the second patient showed tumor shrinkage and disappearance of lung metastases after combination immunotherapy. - A lung lesion measuring over 2.5 cm shrank to less than 1 cm, and a smaller lesion became barely visible on follow-up CT scans. - The target is also present on kidney cancers and glioblastomas, with preclinical success in mouse models of deadly brain cancer reported by McMaster University collaborators.
- Canada's AI for All strategy lacks an equitable implementation framework, risking that AI health tools will disproportionately benefit well-resourced institutions while failing marginalized communities. - AI systems trained on under-representative datasets perform worse for Black, Indigenous, and racialized patients, embedding patterned and predictable equity failures into clinical decision-making. - Research shows AI is not neutral but mirrors human psychological biases and gender stereotypes, leading to women's symptoms being dismissed and reinforcing existing healthcare inequalities. - Experts call for mandatory equity impact assessments, funding for equitable implementation science, and integration of algorithmic bias history into AI literacy training.
- A transatlantic collaboration between the University of Calgary and the Doherty Institute aims to standardize human lung and gut organoid protocols to improve clinical trial success rates. - UK scientists at Cambridge will build a library of standardized, validated organoids from NHS patient cells, funded by a £20 million Medical Research Council grant. - More than 90% of drugs that pass animal testing fail in human trials, underscoring the urgent need for more predictive human-relevant models. - Standardized organoid platforms could enable rapid deployment during future pandemics and advance personalized medicine by identifying patient-specific treatment responses.
- ProSomnus Sleep Technologies received FDA Class II 510(k) clearance for the RPMO₂ OSA Device, marking the first theragnostic device for sleep medicine that integrates precision oral appliance therapy with multi-night physiologic monitoring. - The device features an embedded oximeter that uses buccal mucosa for measurements, demonstrating strong clinical accuracy with 2.94% ARMS for SpO₂ and no systematic bias across skin pigmentation groups in validation studies. - The FDA clearance enables Smart Sleep Medicine workflows, allowing clinicians to monitor OSA treatment continuously and make data-driven adjustments rather than relying on subjective patient feedback. - The innovative intraoral design addresses limitations of conventional pulse oximeters by reducing motion artifacts, providing thermal stability, and potentially minimizing racial bias in oxygen saturation measurements.
- A Phase I/II clinical trial found that high-dose vitamin B3 (niacin) combined with standard therapy improved six-month progression-free survival to 82% in glioblastoma patients, compared to a typical 54%. - The study enrolled 24 patients and demonstrated that niacin can restore function in weakened immune cells, enhancing their ability to target and destroy tumor cells. - Researchers at the University of Calgary caution that the small sample size, short follow-up, and lack of a randomized control group limit the findings, and larger controlled trials are needed. - The team plans to enroll an additional 24 patients by the end of 2026 or early 2027 to further assess niacin's safety and immune system activation.
- St. Michael's Hospital has commenced patient dosing in Arch Biopartners' Phase II trial evaluating LSALT peptide for preventing cardiac surgery-associated acute kidney injury (CS-AKI). - The international multicenter trial targets 240 patients and represents a potential first-in-class therapeutic approach for CS-AKI, which affects up to 30% of cardiac surgery patients. - LSALT peptide works by binding to the DPEP1 enzyme to inhibit organ inflammation, with previous Phase II results showing statistically significant reductions in inflammatory biomarkers. - The company is expanding trial sites to include U.S. centers while also advancing a separate Phase II trial of cilastatin for drug-induced acute kidney injury.
- Avicanna has initiated a Phase I randomized, double-blind, placebo-controlled trial at the University of Calgary to evaluate dose-dependent effects of oral THC on anxiety and stress in 24 healthy adults. - The study will test three different THC doses (6mg, 9mg, and 15mg) using Avicanna's proprietary AVCN319301b capsules featuring Solid Self-Emulsifying Drug Delivery System technology. - Primary endpoints focus on validated psychometric assessments of anxiety and subjective response, with secondary measures including mood, cardiovascular parameters, and pharmacokinetic profiling. - The trial aims to generate high-resolution dose-response data to better define the therapeutic window of oral THC and characterize interindividual variability in response.
- CRS3123 achieved 97% clinical cure rates in Phase 2 trials while demonstrating significantly lower recurrence rates of 4% compared to 23% for vancomycin at day 40. - Multi-omics analysis revealed that CRS3123 preserves gut microbiome diversity and secondary bile acid synthesis better than vancomycin, addressing the primary unmet need in CDI treatment. - The positive Phase 2 results published in The Lancet Infectious Diseases warrant advancement to Phase 3 development for this novel narrow-spectrum antibiotic. - Crestone has completed manufacturing improvements and toxicity studies with NIAID funding, positioning CRS3123 as a potential leading treatment option for CDI.
- A University of Calgary-led randomized controlled trial found that time-restricted feeding significantly reduced Crohn's disease activity by 40% and abdominal discomfort by 50% in just 12 weeks. - The 35-participant study showed that eating within an 8-hour window led to weight loss of 5.5 pounds and improvements in inflammatory markers without requiring calorie restriction. - Participants experienced a 40% reduction in stool frequency and notable improvements in blood markers including lower levels of leptin and PAI-1. - The research suggests intermittent fasting may offer a practical adjunctive strategy for Crohn's disease management alongside standard medical therapy.
- University of Calgary researchers demonstrated that PV-10, Provectus Biopharmaceuticals' rose bengal sodium formulation, activates the STING immune pathway to enhance hepatitis B vaccine responses. - The preclinical study showed PV-10 stabilizes STING dimerization, upregulates pro-inflammatory cytokines, and significantly boosts IFN-gamma secretion by antigen-primed T cells. - This novel mechanism positions PV-10 as a potential safer alternative to traditional vaccine adjuvants like aluminum salts, targeting the $2 billion adjuvant market projected by 2030. - The research suggests PV-10 could help rescue immune non-responders who fail to achieve protection with current vaccines, addressing an unmet medical need in approximately 10% of healthy individuals.
